St. Louis Arch Angels is an angel investment group focused on providing seed, startup, and early-stage capital primarily within the St. Louis region. Established in January 2005 and based in St. Louis, Missouri, the group invests between $25,000 and $100,000 per individual transaction, with collective investments ranging from $250,000 to $750,000. The organization aims to support high-potential startups from the local ecosystem, thereby enhancing the region's capacity to finance innovation. St. Louis Arch Angels seeks to fill the funding gap often overlooked by institutional venture capital firms, retaining investments for up to eight years to foster the growth and success of their portfolio companies.
Maximum Fidelity Surgical Simulation specializes in the development of advanced medical training solutions, focusing on the creation of hyper-realistic surgical simulators. Their flagship product is a human-like mechanical cadaver system designed to enhance medical education by accurately mimicking human anatomy and physiological responses. This system employs realistic materials and technologies, such as Simblood and a pulsatile pump, to replicate blood flow and circulatory functions. By offering an immersive training environment, Maximum Fidelity enables medical personnel to practice surgical techniques and trauma care without the ethical concerns associated with using live subjects. The company's innovative approach is applicable across various fields, including military trauma training, biomedical device testing, and veterinary education, ensuring that learners gain critical hands-on experience in a safe and controlled setting.
Peptyde Bio
Pre Seed Round in 2022
Peptyde Bio is an Agtech startup focused on developing bio-fungicidal technology to combat fungal diseases. The company specializes in natural antimicrobial peptides (AMPs) derived from plants, positioning itself as a key supplier in this niche market. By leveraging these innovative compounds, Peptyde Bio aims to provide more affordable and effective treatment options for patients suffering from fungal infections.
SentiAR
Venture Round in 2021
SentiAR, Inc. is a digital health company based in St. Louis, Missouri, specializing in 3D augmented reality solutions for interventional medical procedures. Founded in 2017 as a spin-off from Washington University, SentiAR has developed a platform that offers real-time holographic visualization of patients' anatomical structures and catheter locations. This technology integrates data from CT, MRI, and real-time mapping systems to create a controllable 3D holographic interface. The platform aims to enhance the delivery of care by allowing clinicians to visualize complex cardiac anatomy directly over the patient, thereby improving the treatment of cardiac arrhythmias during catheterization procedures. SentiAR is in the process of preparing its platform for submission to the FDA.
Impetus Agriculture
Seed Round in 2021
Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.
Sequoia Sciences
Seed Round in 2020
Sequoia Sciences, Inc. is a pharmaceutical company based in Saint Louis, Missouri, focused on discovering and developing innovative treatments for bacterial infections and cancers. Founded in 1999, the company engages in preclinical development programs aimed at addressing unmet medical needs, particularly for lung infections in cystic fibrosis patients and recurrent urinary tract infections. Sequoia's portfolio includes small molecules and vaccines designed to improve the quality of life for individuals affected by chronic bacterial infections and cancers. The company collaborates with laboratories, universities, clinical research sites, and private enterprises to advance its research and development efforts. Additionally, Sequoia applies its expertise in microscale structure determination to elucidate the structures of natural products and synthetic intermediates, supporting both academic and industrial research initiatives.
Amplified Sciences
Seed Round in 2020
Amplified Sciences LLC is a molecular diagnostics company focused on the early detection of debilitating diseases, particularly pancreatic cancer and kidney disease. Utilizing an ultra-sensitive molecular sensing technology licensed from Purdue University, the company’s platform can detect disease markers at the single molecule level, enabling accurate diagnosis from bodily fluids such as urine and saliva. This versatile technology is designed for scalability to point-of-care applications, allowing for effective disease screening with a favorable cost structure. Amplified Sciences has developed a working prototype and has published proof of concept data, positioning itself to meet significant unmet medical needs in diagnostics. Founded in 2016 and based in West Lafayette, Indiana, the company was previously known as Nutrabiotix.
CoverCress
Venture Round in 2020
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.
FinLocker
Venture Round in 2019
FinLocker, LLC is a financial technology company founded in 2014 and based in St. Louis, Missouri. It develops a consumer-enabled financial data platform that facilitates the loan process for mortgages and other financial products. The platform serves both businesses and consumers by streamlining loan transactions and enhancing the overall financial experience. For businesses, FinLocker provides tools that cut costs, reduce fraud, and mitigate risks while improving customer satisfaction and operational efficiency. For consumers, the platform simplifies the loan application process, minimizes paperwork, and enables better management of personal finances. Using consumer consent, FinLocker captures essential borrower data and employs intelligent analytics to offer tailored loan product recommendations based on individual financial profiles.
Ryvit
Seed Round in 2019
Ryvit develops an integration software that delivers seamless flow of data between premise and software used in the construction industry. The software integrates software application to enterprise resource product, customer relationship management, e-commerce, social apps, and specialty industry-specific system without exhausting development resources, empowering companies to experience the ease of intelligent integrations, driving profit through automation and optimization of the applications in use. Ryvit is headquartered in Saint Louis, Missouri.
IDEATE Medical
Series A in 2019
IDEATE Medical develops sterilization technology for the safe and rapid terminal sterilization of all endoscopic devices. The mission of IDEATE Medical is to lower the infection risk from the 75 million endoscope procedures conducted in the U.S. each year. IDEATE Medical understands the importance of efficacy, compatibility, and throughput and has developed a unique, innovative, low-temperature sterilization technology for the safe and rapid terminal sterilization of all endoscopic devices for every procedure. Our technology utilizes the benefits of Vapor Hydrogen Peroxide (VHP) sterilization technology but incorporates key innovations to address the specific challenges associated with the terminal sterilization of long multi-channel endoscopic medical devices. With its innovations, the most challenging endoscopic devices can be terminally sterilized in 30 minutes with no impact on the endoscopic device.
Balance the Superfood Shot
Seed Round in 2018
Balance the Superfood Shot is a health supplement company based in Kansas City that specializes in nutritional food supplements aimed at promoting the daily intake of fruits and vegetables. Founded in 2011, the company offers a product line that includes premium health and nutrition items designed to enhance preventative health. Their flagship product provides consumers with a convenient shelf-stable tonic that delivers half a day's serving of organic fruits and vegetables, along with essential multivitamins and nutrients. This approach supports individuals in achieving a healthier, more balanced lifestyle through easy access to vital nutrients.
ProteoSense
Seed Round in 2018
ProteoSense, LLC specializes in developing advanced pathogen detection solutions for the food industry. Founded in 2013 and based in Columbus, Ohio, the company offers RapidScan, a handheld testing system that enables quick identification of food-borne pathogens such as E. coli, salmonella, listeria, and campylobacter. This system is designed for use in time-critical and remote applications, catering to various stakeholders in the food supply chain, including growers, packers, processors, shippers, and wholesalers. The testing technology allows for immediate results without the need for enrichment time, making it accessible for use by non-technical personnel in field and manufacturing settings. ProteoSense is committed to enhancing food safety and quality through its innovative solutions.
Rozzy Learning Company
Seed Round in 2018
Rozzy Learning Company mission is to bring hands-on STEAM (Science, Technology, Engineering, Art, Math) programs and resources to young learners and teachers to promote curiosity, critical thinking skills, and exploration. They focus on STEAM careers because they are the fastest growing, highest paying jobs in the world. By introducing kids to STEAM early on, you are setting them up for success in and outside of school. Unlike other STEAM companies, they have affordable programs that don‘t require expensive technology or materials. Bonus? Their programs fit into teachers’ busy schedules!
Viosera
Seed Round in 2018
Viosera Therapeutics, Inc. is focused on developing therapies to combat antibiotic resistance, particularly targeting methicillin-resistant Staphylococcus aureus (MRSA). Founded in July 2016, the company has its headquarters in Sunnyvale, California, and an additional office in St. Louis, Missouri. Viosera is known for its innovative approach that utilizes artificial intelligence to predict and block the evolution of drug resistance in both cancer and bacterial infections. Its primary product, VT1, is specifically designed to treat MRSA bloodstream infections, allowing healthcare providers to effectively manage and suppress antibiotic resistance, ultimately aiming to enhance patient outcomes.
CheckTheQ
Seed Round in 2018
CheckTheQ, Inc. is a company based in Saint Louis, Missouri, founded in 2016, that offers a subscription service for tracking and communicating real-time wait times. The company primarily serves airports, stadiums, and various venues, providing them with valuable data to optimize operations and enhance the customer experience. CheckTheQ's platform integrates counting and customer response technologies, enabling facilities to monitor restroom usage and receive immediate feedback from passengers. This approach helps to reduce wait times, improve staffing efficiency, and ultimately boost customer satisfaction. By offering an affordable solution tailored for small, regional, and international airports, CheckTheQ aims to enhance operational effectiveness and contribute positively to the overall traveler experience.
KaloCyte
Seed Round in 2018
KaloCyte, Inc. is a pre-clinical stage healthcare biotech company based in Baltimore, Maryland, founded in 2016. The company focuses on developing ErythroMer, a dried and bio-inspired artificial red blood cell intended to address life-threatening blood loss in situations where stored red blood cells are either unavailable or unsuitable for use. ErythroMer aims to provide context-dependent oxygen delivery while minimizing complications such as vasoconstriction and methemoglobin formation. This innovative approach seeks to enhance trauma care services by offering an effective alternative for managing traumatic hemorrhage when traditional blood supplies are inadequate.
Lean Media
Seed Round in 2018
Lean Media, Inc. specializes in cookieless digital advertising services tailored for agribusiness and rural community advertisers. Founded in 2014 and headquartered in Chesterfield, Missouri, the company utilizes a sophisticated audience targeting platform that leverages geo-targeting technology alongside consumer psychographic, demographic, and behavioral insights. By comparing IP addresses with consumer databases, Lean Media enables advertisers to engage individuals at the consumer level, as well as target specific business categories or locations. Their innovative approach aims to enhance engagement and minimize waste in advertising campaigns, providing a reliable solution for reaching target audiences effectively.
Transactly
Pre Seed Round in 2018
Transactly is a real estate technology platform founded in 2018 and based in St. Charles, Missouri. It focuses on organizing and coordinating the closing process of real estate transactions across the United States. As the first tech-enabled transaction coordinator service, Transactly provides customers with a dedicated coordinator backed by a comprehensive support team. The platform aims to streamline real estate transactions for home buyers and sellers, enhancing transparency and efficiency. By managing the various tasks involved in the transaction process, Transactly enables real estate professionals, such as brokers and agents, to improve their service offerings and increase their revenue potential.
Swipesum
Angel Round in 2018
Swipesum, Inc. is a payment processing consulting company based in Saint Louis, Missouri, founded in 2016. The company operates a platform that connects businesses with a global network of payment providers and methods, aiming to reduce credit and debit card processing fees, which represent a significant operating expense for U.S. businesses. Swipesum's proprietary technology simplifies the complex landscape of payment solutions, enabling businesses to identify the most suitable options for their needs. The platform allows merchants to initiate an auction where credit card processors compete for their business, ensuring cost-effective processing systems. Additionally, Swipesum offers consulting services that leverage its AI-powered software, Staitment, to streamline the analysis of processing statements for financial institutions and vendors. By providing these services at no upfront cost to businesses, Swipesum generates revenue through recurring finders fees from payment companies they refer, ensuring transparency in their operations. In 2019, Swipesum advised on over $8 billion in processing volume, showcasing its impact in optimizing payment solutions for its clients.
Aptimmune
Series B in 2018
Aptimmune is a biotechnology company based in St. Louis, Missouri, founded in 2010. The company specializes in developing mucosal vaccines for swine to combat viral diseases, specifically targeting Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza A virus. Aptimmune employs innovative technologies, including its proprietary pig alveolar macrophage cell line ZMAC, to create effective nasal delivery vaccines. These advancements aim to provide animal breeders with lasting immune responses and enhanced disease protection, contributing to the overall health and productivity of swine populations.
CoverCress
Venture Round in 2017
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.
Nexmatix
Seed Round in 2017
NexMatix is a developer and manufacturer focused on enhancing the efficiency of pneumatic systems through innovative products. The company specializes in smart valves, particularly directional control valves, which are recognized as some of the most inefficient components in the industry. These valves are equipped with embedded sensors that continuously monitor for leaks, enabling users to identify faults related to pressure and functionality. By improving the performance of these systems, NexMatix aims to reduce operational costs and lower carbon footprints, contributing to more sustainable industrial practices.
Cardiaform
Seed Round in 2017
Cardiaform is a medical device company developing devices to diagnose and treat cardiovascular disease. Its devices will enable instantaneous high density, high definition electrical maps to support mapping unstable arrhythmias (ventricular tachycardia), reduce procedure time from 3-4 hours to less than 1 hour, and provide improved procedural success using only a single catheter.
Kogent Surgical
Seed Round in 2017
Kogent Surgical, LLC specializes in the design, manufacture, and marketing of surgical and neurosurgical instruments. Founded in 2011 and based in Chesterfield, Missouri, the company offers a range of products including curettes, elevators, ball tip probes, forceps, knives, and suction tubes, among others. Kogent Surgical is recognized as an industry leader in neurosurgical instruments, providing high-quality products suited for electrosurgery and microsurgery. The instruments are crafted from lightweight, non-magnetic titanium, allowing for both disposable and reusable options during surgical procedures. In addition to its product offerings, the company also provides surgical instrument repair and restoration services. Kogent Surgical distributes its products worldwide and aims to deliver superior service and cost-effective solutions to its customers.
Euclises Pharmaceuticals
Venture Round in 2016
Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.
Greetabl
Seed Round in 2016
Greetabl is an online gift platform that specializes in creating unique and personalized gifts. It allows users to easily transform their photos into greeting cards that also function as gift boxes. Customers can enhance their gifts by selecting from a variety of options, including gift cards and chocolates, with prices starting at $20. The platform is designed to enable individuals to send thoughtful presents to their friends and loved ones, making gifting simple and accessible.
FocalCast
Seed Round in 2016
FocalCast LLC, founded in 2013 and based in St. Louis, Missouri, provides an interactive web-based platform designed for market research. The company specializes in facilitating real-time collaboration, enabling users to share and annotate documents and presentations seamlessly from any device without the need for downloads. FocalCast's services cater to global brands and marketing agencies, offering tools for live annotation, polling, and data collection. This innovative approach allows researchers to engage participants effectively, enhancing the overall market research process through its user-friendly platform.
Radialogica
Venture Round in 2016
Radialogica LLC is a healthcare information technology company that specializes in software solutions for radiation oncology. Incorporated in 2011 and headquartered in St. Louis, Missouri, it offers the fullAccess platform, which facilitates the display, communication, and analysis of radiotherapy treatment plans, diagnostic images, and other patient data. This integrated platform includes various modules, such as fullView, which provides a vendor-independent visualization environment for treatment plans; fullReport, which helps analyze and benchmark treatment plans; and fullExchange, designed for the annotation and sharing of diagnostic images and treatment plans among clinicians. Radialogica also provides OncoInformatix, a web-based tool for the acquisition, aggregation, analysis, and reporting of radiotherapy treatment data. The company's solutions are utilized by healthcare providers and payers across the United States, aimed at enhancing the efficiency and quality of cancer treatment.
SmashToast
Seed Round in 2016
SmashToast, Inc. is a technology company founded in 2014 and based in Rochester, Illinois, with a customer service center in Austin, Texas. The company specializes in developing innovative hardware and software solutions that facilitate home automation. Its flagship product is a Bluetooth-enabled device that allows users to control various home electronics, such as televisions, sound bars, air conditioners, and space heaters, through a mobile application. This device eliminates the need for multiple remote controls and cumbersome wires, providing a seamless user experience without line-of-sight constraints. By connecting homes to smartphones, SmashToast empowers customers to monitor and manage their household activities more efficiently.
Galera Therapeutics
Series B in 2016
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, dedicated to developing innovative therapeutics aimed at enhancing the effectiveness of radiotherapy for cancer patients. The company's lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer. Additionally, GC4419 is being evaluated in Phase IIa trials for the treatment of radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing another candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. The company's research is focused on targeting oxygen metabolic pathways to improve patient outcomes in radiation therapy, and GC4419 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration.
Dexer
Seed Round in 2016
Dexer is a heads-up, customized speech application and service that streamlines data collection and accessibility across industries.
Euclises Pharmaceuticals
Venture Round in 2015
Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.
Confluence Life Sciences
Series B in 2015
Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, founded in 2010. The company specializes in rational drug design, focusing on mechanistically novel kinase inhibitors aimed at addressing unmet medical needs in cancer and chronic inflammatory diseases. Its KINect technology platform is pivotal for identifying and developing new protein kinase drugs that target crucial enzymes involved in cancer growth, survival, and metastasis, as well as in modulating chronic inflammation. Unlike many competitors, Confluence Life Sciences explores novel binding sites on challenging kinase targets and previously un-targeted kinases. The company is driven by a team of experts with significant pharmaceutical experience, allowing it to pursue innovative strategies beyond traditional industry focus. To enhance its business potential, Confluence Life Sciences is also establishing scientific and business collaborations, fostering a pipeline strategy of discovery, development, and partnership. As of August 2017, it operates as a subsidiary of Aclaris Life Sciences, Inc.
CoverCress
Series A in 2015
CoverCress Inc. is a biotechnology company based in St. Louis, Missouri, focused on developing and commercializing field pennycress as an oilseed crop. Founded in 2013, the company aims to produce oil for industrial and renewable fuels, as well as meal for nutritious livestock feed. CoverCress specializes in crop breeding services that enhance soil cover during corn harvest and soybean planting, allowing farmers to maximize yields through sustainable agricultural practices. The company is dedicated to utilizing low-input methods to create a feedstock for low carbon intensity biofuels, contributing to more efficient and environmentally friendly agricultural solutions.
Euclises Pharmaceuticals
Series A in 2015
Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.
GeneriCo
Seed Round in 2015
GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic drugs. Founded in 2013 and headquartered in Saint Louis, Missouri, with additional offices in Bengaluru, Italy, and South Korea, GeneriCo focuses on niche generic pharmaceuticals that are often overlooked by larger competitors. The company targets foundational medicines in key therapeutic areas, including cardiovascular health, pain management, central nervous system disorders, oncology, and aging-related conditions. GeneriCo distinguishes itself through its expertise in complex formulations and embedded drug delivery technologies, addressing market needs that are typically neglected by mid-sized and large generic firms. The company's global reach enables it to serve a diverse customer base.
Benson Hill
Seed Round in 2015
Benson Hill is an agricultural technology company that specializes in crop improvement and soy protein innovation. The company focuses on unlocking the natural genetic diversity of plants to develop healthier, more sustainable food and ingredients. Its proprietary CropOS platform leverages machine learning and big data alongside traditional breeding techniques to streamline and expedite the product development process. Benson Hill operates a Crop Accelerator designed for rapid prototyping and is actively developing a seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company generates revenue from both proprietary and non-proprietary product categories, with proprietary revenue stemming from the sale of its unique bean varieties.
RnAgri
Seed Round in 2015
RNAgri is a company based in St. Louis, Missouri, that specializes in innovative technology for producing ribonucleic acid (RNA). Founded in 2011, the company focuses on addressing the challenges associated with the large-scale production of exogenous RNA interference (RNAi) products. By utilizing a large-scale fermentation process, RNAgri enables farmers to enhance the protection and growth of their crops and livestock through the cost-efficient production of RNA. This technology aims to improve agricultural practices and contribute to more sustainable farming solutions.
Cardialen
Series B in 2015
CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.
RnAgri
Seed Round in 2015
RNAgri is a company based in St. Louis, Missouri, that specializes in innovative technology for producing ribonucleic acid (RNA). Founded in 2011, the company focuses on addressing the challenges associated with the large-scale production of exogenous RNA interference (RNAi) products. By utilizing a large-scale fermentation process, RNAgri enables farmers to enhance the protection and growth of their crops and livestock through the cost-efficient production of RNA. This technology aims to improve agricultural practices and contribute to more sustainable farming solutions.
Immunophotonics
Series A in 2015
ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for cancer, specifically targeting metastatic solid tumors. Founded in 2008 and located in Columbia, Missouri, the company has created a proprietary drug product designed to function as a minimally invasive therapeutic cancer vaccine. This product is administered through intratumoral injection following tumor ablation, leveraging tumor-associated neoantigens to stimulate a systemic anti-tumor immune response. By transforming the process of tumor ablation into a therapeutic approach, ImmunoPhotonics aims to enhance treatment options for patients with late-stage metastatic cancers. The company has also established a strategic partnership with Veterinary Cancer Therapeutics, LLC to further its mission in cancer treatment.
S4
Seed Round in 2015
S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.
Elira
Seed Round in 2015
Elira, Inc. is a neurostimulation company based in St. Louis, Missouri, founded in 2015. The company specializes in developing a drug-free wearable device aimed at helping overweight adults manage their weight by suppressing appetite. This innovative device offers a non-invasive method to modulate the central nervous system, providing users with a means to gain control over their eating habits. By effectively reducing appetite, Elira's technology supports individuals in achieving their health and lifestyle goals.
SixPlus
Seed Round in 2015
SixPlus is an online platform that simplifies the process of finding and booking private and semi-private venues for group events, catering to corporate event planners and individuals. The service allows users to browse a selection of venues, manage bookings, contracts, and communication in one convenient location. Clients can utilize SixPlus for a variety of gatherings, including board dinners, team lunches, and holiday parties, across major cities such as New York, Washington DC, Boston, Los Angeles, San Francisco, and Chicago. By facilitating reservations for groups of six or more, SixPlus streamlines the event planning process, making it easier for users to build proposals and secure the ideal venue for their needs.
Epharmix
Seed Round in 2015
Epharmix, Inc. is a digital healthcare company that specializes in developing clinically validated, condition-specific communication tools for the healthcare industry. Founded in 2015 and based in Saint Louis, Missouri, Epharmix provides digital interventions designed to enhance patient-physician engagement, automate the collection of clinical data, and alert healthcare providers for effective chronic care management. Its products aim to improve care for underserved patients while also reducing the workload of care teams, ultimately enhancing patient engagement and health outcomes.
Coolfire
Seed Round in 2014
Coolfire Solutions, Inc., established in 2010 and headquartered in St. Louis, Missouri, specializes in developing situational awareness technology. The company's flagship product, Ronin, is a mobile-first platform that connects people, assets, and information, enabling swift decision-making and action-taking. Coolfire's patented technology creates a digital workspace, keeping teams organized and informed, serving a diverse range of customers including corporate entities like Enterprise Rent-A-Car and government agencies such as the U.S. Department of Defense.
CellARide
Seed Round in 2014
CellARide is a technology company specializing in automotive marketing and safety recall communications. It has developed a platform that enables users to create mobile brochures for their vehicles, facilitating direct communication with potential customers. By leveraging widely used mobile messaging technologies, CellARide provides automotive marketers, manufacturers, and advocacy organizations with consumer insights, compliant communication tools, and a data capture platform. This approach allows clients to engage effectively with consumers and obtain real-time, actionable data, enhancing their marketing efforts. Through its innovative solutions, CellARide aims to streamline the marketing process for automotive brands and dealerships, making it easier to connect with shoppers.
IV Diagnostics
Private Equity Round in 2014
IVDiagnostics, Inc. is a company that specializes in the development, testing, and marketing of diagnostic tools aimed at detecting rare circulating tumor cells (CTCs) and blood-borne diseases. Established in 2010 and headquartered in Crown Point, Indiana, the company offers a range of products, including CTC cancer assays and minimally invasive molecular diagnostics. These tools are designed to diagnose various types of cancer, such as breast, colon, kidney, lung, ovarian, pancreatic cancers, and leukemia. By focusing on CTCs, which are cancer cells that circulate in the blood and can lead to metastasis, IVDiagnostics aims to enhance early cancer detection and improve patient outcomes. Their innovative diagnostic technology allows healthcare professionals to monitor and detect CTCs in real time, providing critical insights without the need for extensive blood tests.
Time to Cater
Angel Round in 2014
Time to Cater is a web-based platform designed to assist companies and individuals in organizing catered events without incurring additional costs. Users simply input their event details, food preferences, and budget into the platform, which then manages the entire catering process. This includes coordinating with caterers, selecting menus, and ensuring quality control. By streamlining communication and order placement, Time to Cater eliminates the time-consuming task of contacting multiple caterers for availability and pricing. The service is funded through commissions from caterers within its Preferred Caterer Network, allowing clients to enjoy a seamless catering experience from start to finish at no extra charge.
PolicyEngage
Seed Round in 2014
TrackBill is a provider of legislative tracking and reporting software that helps users stay informed about significant legislative actions, including bill introductions, amendments, hearings, and votes. The platform offers real-time alerts, enabling users to respond promptly to changes in legislation. TrackBill simplifies the process of legislative reporting by allowing clients to generate professional documents in various formats such as Word, PDF, and Excel. Additionally, it offers customizable and auto-updating website feeds, enhancing the accessibility of legislative information. This focus on workflow automation supports public affairs teams in managing their activities efficiently while ensuring stakeholders remain informed.
Aisle411
Series A in 2013
Aisle411 Inc., founded in 2008 and headquartered in St. Louis, Missouri, specializes in providing mobile in-store location services for retailers. The company's innovative platform enables shoppers to easily navigate retail environments by mapping products, offers, and shopping lists based on aisle location. It enhances the shopping experience by delivering contextually relevant information to consumers as they move through stores. For retailers, Aisle411's technology helps them engage shoppers at the shelf, facilitating access to product inventory and location data. The platform is designed to collect and organize this information, allowing for improved merchandising insights and customer engagement. Additionally, Aisle411 collaborates with leading indoor positioning technology providers to enhance its services, ultimately driving higher customer satisfaction and simplifying the overall shopping experience.
Euclises Pharmaceuticals
Seed Round in 2013
Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.
Bacterioscan
Series A in 2013
BacterioScan, Inc. is a medical device company based in St. Louis, Missouri, focused on diagnosing and treating infectious diseases. The company has developed the 216Dx UTI System, which detects bacteria indicative of urinary tract infections (UTIs) in clinical urine samples and helps identify suitable antibiotic treatments. Additionally, BacterioScan offers the 216R Antibiotic Susceptibility Testing System, designed to detect bacterial infections, assess antibiotic resistance, and provide clinicians with tailored antimicrobial resistance profiles. Its precision bench-top systems facilitate rapid detection and real-time quantification of microbial growth, significantly enhancing laboratory efficiency compared to traditional plating methods. This innovative approach not only aids clinicians in personalizing patient care but also supports researchers in accelerating the development of new antibiotics. BacterioScan's technology aims to improve the quality of antibiotic therapy and mitigate the risks associated with antibiotic resistance.
Adarza BioSystems
Seed Round in 2013
Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, founded in 2008. The company specializes in developing a rapid and label-free biological assay platform that measures clinical and point-of-care samples. This innovative platform employs diagnostic arrayed imaging reflectometry (AIR) to enable the simultaneous detection of hundreds of analytes from a single drop of fluid, allowing healthcare professionals to conduct sophisticated tests with high sensitivity and specificity. By significantly reducing the time required for testing, Adarza BioSystems aims to enhance diagnostic capabilities in various healthcare settings.
Acera Surgical
Seed Round in 2013
Acera Surgical, Inc. specializes in developing fully synthetic surgical materials that serve as resorbable scaffolds for soft tissue repair and regeneration. The company's innovative products include hybrid-scale fiber matrices designed to mimic the structure of human tissue, providing flexibility and strength while resisting enzymatic degradation. These materials enhance surgical efficiency, minimize complications and costs, and promote superior clinical outcomes. By offering an alternative to traditional biologics, Acera's solutions empower healthcare professionals to improve patient healing effectively.
Elemental Enzymes
Seed Round in 2013
Elemental Enzymes Inc. is a manufacturer of specialized enzymes designed for optimal performance in challenging environments, both in agriculture and industrial applications. The company produces a diverse range of enzymes, including those that degrade cellulose and starches for fuel production, and stable enzymes that provide eco-friendly alternatives to harsh chemicals used in processes like fracking. Additionally, Elemental Enzymes develops solutions for capturing and storing carbon dioxide and for breaking down proteins and antibiotics to prevent contamination of water supplies. The company also offers customized enzyme solutions tailored to address specific environmental contaminants, as well as enzymes for various non-environmental applications. Founded in 2011 and based in Columbia, Missouri, Elemental Enzymes was previously known as Spogen Biotech, Inc. and leverages patented technologies and scientific advancements to meet the evolving needs of its customers.
Akermin
Venture Round in 2013
Akermin, Inc. is a biocatalyst development company based in St. Louis, Missouri, founded in 2003. The company specializes in innovative solutions for the removal of carbon dioxide (CO2) from industrial gas streams, utilizing biocatalysis and nanotechnology. Akermin has developed proprietary delivery systems that integrate enzymes into traditional chemical absorption processes, allowing for effective CO2 capture. In addition to its focus on carbon capture, the company has demonstrated capabilities in creating biofuel cells and is exploring commercial applications in various sectors, including food processing, biofuels, chemicals, and pharmaceuticals. The technology targets a range of industries in the United States, positioning Akermin as a key player in advancing environmentally sustainable practices.
Tunespeak
Seed Round in 2013
Tunespeak, LLC operates a musician-to-fan loyalty platform that rewards users for engaging with music and related content. Founded in 2011 and based in St. Louis, Missouri, the platform allows users to earn points by listening to music, watching videos, viewing photos, and sharing content with friends. Users can accumulate points not only for their own activity but also for enabling their friends to participate in contests or raffles for every song, picture, and video shared. Through this unique engagement model, Tunespeak aims to enhance the connection between musicians and their fans while offering incentives such as tickets, experiences, and merchandise.
BenchmarkONE
Seed Round in 2012
BenchmarkONE develops sales and marketing automation software tailored for small and mid-sized businesses. The company offers an integrated platform that includes customer relationship management (CRM) tools and sales automation features, allowing users to monitor contacts' activities, track deals, manage communications, and segment their audience. Additionally, BenchmarkONE provides email marketing capabilities with a user-friendly drag-and-drop email builder and marketing automation tools designed to engage visitors, prioritize leads, and optimize campaign investments. Originally known as Hatchbuck, Inc., the company rebranded to BenchmarkONE in June 2020 and has been operational since 2010, with its headquarters in St. Louis, Missouri. As of September 2019, BenchmarkONE functions as a subsidiary of Benchmark Internet Group, LLC.
NeuroLutions
Seed Round in 2012
NeuroLutions Inc. is a company based in St. Louis, Missouri, focused on developing brain-computer interface (BCI) devices aimed at restoring functions for patients disabled due to neurological injuries, particularly stroke survivors. Founded in 2007, NeuroLutions employs non-invasive electroencephalography (EEG) technology to capture brain activity without the need for implanted electrodes. The EEG data is wirelessly transmitted to a tablet, where it is analyzed to interpret the patient's intended muscle movements. This innovative approach enables users to facilitate muscle re-education and helps maintain or improve their range of motion, thereby enhancing rehabilitation outcomes for individuals with movement impairments.
Cardialen
Angel Round in 2012
CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.
Kypha
Series A in 2012
Kypha Inc. is a life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Through its innovative platform, Kypha provides rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. The company's approach facilitates testing across diverse settings, from home health care to clinical laboratories, ultimately aiming to improve patient outcomes by optimizing treatment strategies based on real-time immune insights. Since its incorporation in 2009, Kypha has attracted significant funding and built a strong network of scientific and clinical expertise to support its mission.
Decide
Seed Round in 2012
Decide operates an interest-based social platform that caters to various topics, including gaming, music, and politics. The company provides native advertising solutions that allow brands to effectively engage with their target audiences. It offers tools for audience development, such as polls, contests, quizzes, and feedback mechanisms, enabling publishers to activate user engagement through customizable actions like newsletter subscriptions and social media follows. Additionally, Decide assists in campaign planning, content creation, and performance optimization, while allowing real-time measurement of results. The platform leverages an in-house artificial intelligence, known as Neo, which utilizes machine learning to analyze vast amounts of data and make informed advertising decisions. Founded in 2008 and headquartered in Saint Louis, Missouri, with an additional office in New York, Decide aims to enhance the advertising experience by connecting advertisers with relevant publishers and users.
Euclises Pharmaceuticals
Seed Round in 2012
Euclises Pharmaceuticals, Inc. is engaged in the research, development, and commercialization of innovative medicines targeting inflammation and oncology. Founded in 2011 and headquartered in Saint Louis, Missouri, the company focuses on creating novel pain and cancer medications that promise enhanced safety profiles compared to current therapies. The firm is built on pioneering inventions by Dr. John Talley, a renowned medicinal chemist known for developing Celebrex among other approved drugs. Euclises aims to introduce new compounds that provide improved efficacy and safety, positioning itself as a leader in the pharmaceutical industry. The company operates from the BioGenerator Accelerator Labs, where it continues to advance its research initiatives.
Bonfyre
Angel Round in 2012
Bonfyre Inc. is an employee engagement platform founded in 2013 and based in Saint Louis, Missouri. The company focuses on transforming workplace culture by providing technology that enhances employee recognition, communication, feedback, and event management. Its mobile-first platform offers real-time communication tools such as announcements, targeted broadcasts, and pop surveys, which help organizations foster camaraderie, align their culture, and gather valuable HR insights. By modernizing employee communications, Bonfyre enables companies to build stronger relationships and increase engagement, ultimately promoting a collaborative and innovative work environment.
Traxxsson
Seed Round in 2012
Traxxsson is a biotechnology company that develops diagnostics for cancer using protein biomarkers. It uses a proprietary panel of biomarkers to identify at-risk patients who have questionable radiology images. It has three tests: PRO CancSure to identify prostate cancer patients in need of aggressive treatment, BRE CancSure to confirm the presence of breast cancer in women with positive mammograms, and LNG CancSure to confirm the presence of lung cancer in patients with positive low-density CAT scan results. The company was founded in 2009 and is based in St. Louis, Missouri.
Nawgan
Seed Round in 2011
Nawgan offers a brain-friendly functional beverage developed to provide both long and short-term benefits for the brain. Nawgan contains citicoline (a combination of choline and cytidine); Alpha-GPC (Alpha-glyceryl phosphorylcholine – claimed to increase acetylcholine in the brain); lycopene; caffeine (100mg); and natural vitamin E. Unlike many products in the cognitive function market, claims made by Nawgan were supported by research on the end product rather than extrapolations based on literature about individual ingredients.
Euphrates Vascular
Seed Round in 2011
Euphrates Vascular is a medical technology company based in St. Louis, Missouri, that focuses on innovative solutions for the treatment of stroke, heart disease, and other conditions. The company has developed a proprietary magnetically-enhanced diffusion (MED) system that utilizes magnet-based technology to dissolve blood clots more rapidly than existing treatment options. This system aims to improve the efficacy of FDA-approved clot-busting medications, potentially reducing mortality rates associated with stroke and cardiovascular diseases. In addition to the MED system, Euphrates Vascular offers MED MicroBeads, which are designed to deliver therapeutic agents directly to clots during thrombolysis therapy, and a touch screen-operated MED Workstation. Founded by physicists with extensive experience in medical technology, the company continues to advance its pioneering approaches in the healthcare sector, attracting interest from investors and media alike.
Katalyst Surgical
Seed Round in 2011
Katalyst Surgical, LLC is a manufacturer based in Chesterfield, Missouri, specializing in the design and production of ophthalmic surgical instruments. Established in 2010, the company provides a range of products including titanium cannulas, forceps, hooks, manipulators, LASIK instruments, needle holders, phaco choppers, scissors, and speculums. Katalyst Surgical is focused on enhancing surgical techniques, particularly in membrane peeling, by offering both anterior and posterior surgical tools. Their offerings are available online, catering to the needs of medical practitioners and facilitating effective surgical procedures.
Somark Innovations
Venture Round in 2009
Somark Innovations specializes in advanced identification solutions for laboratory animals, focusing on enhancing the integrity of the chain of custody. The company has developed chip-less radio frequency identification tattoos that offer accurate and consistent identification, promoting both animal welfare and data integrity. By improving the identification process, Somark aims to facilitate better scientific outcomes for researchers and support companies engaged in research advancements. In addition to its primary focus on lab animal identification, Somark also provides inventory management identification systems for various applications, including automotive parts, documents, and casino chips.
Akermin
Series A in 2007
Akermin, Inc. is a biocatalyst development company based in St. Louis, Missouri, founded in 2003. The company specializes in innovative solutions for the removal of carbon dioxide (CO2) from industrial gas streams, utilizing biocatalysis and nanotechnology. Akermin has developed proprietary delivery systems that integrate enzymes into traditional chemical absorption processes, allowing for effective CO2 capture. In addition to its focus on carbon capture, the company has demonstrated capabilities in creating biofuel cells and is exploring commercial applications in various sectors, including food processing, biofuels, chemicals, and pharmaceuticals. The technology targets a range of industries in the United States, positioning Akermin as a key player in advancing environmentally sustainable practices.
Appistry
Series A in 2005
Appistry Inc. specializes in developing bioinformatics tools, cloud services, and software solutions to facilitate genomically enhanced medicine for healthcare institutions. The company provides a range of products, including Appistry CloudDx, which supports patient-centered translational research and the integration of genome-scale tests into routine patient care. Their offerings also include CloudDx Translational, a solution for centralizing data and communication across various research projects, as well as tools for analyzing whole genomes, exomes, and tumor-normal pair data. Additionally, Appistry's GenomePilot and Genome Analysis Toolkit help bioinformaticians and researchers navigate complex next-generation sequencing (NGS) analysis processes and derive actionable insights from NGS datasets. The Cancer Genome Analysis Suite and Variant Annotation and Analysis Suite further enhance the company's capabilities by providing integrated tools for addressing challenges in cancer genomics and variant analysis. Founded in 2001 and based in St. Louis, Missouri, Appistry was previously known as Tsunami Research, Inc. before rebranding in 2005.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.